search
Back to results

Imatinib Mesylate in Treating Patients With HIV-Related Kaposi's Sarcoma

Primary Purpose

Sarcoma

Status
Completed
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
imatinib mesylate
Sponsored by
AIDS Malignancy Consortium
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Sarcoma focused on measuring AIDS-related Kaposi sarcoma, recurrent Kaposi sarcoma

Eligibility Criteria

18 Years - 120 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

DISEASE CHARACTERISTICS: Histologically confirmed Kaposi's sarcoma (KS) involving at least 1 of the following areas: Skin Lymph nodes Oral cavity Gastrointestinal tract* Lungs* NOTE: *Must be asymptomatic or minimally symptomatic AND does not require systemic cytotoxic therapy Serological documentation of HIV infection, as evidenced by positive enzyme-linked immunosorbent assay (ELISA), Western Blot test, or other federally approved licensed HIV test At least 5 measurable, non-irradiated, cutaneous indicator lesions Patients must have 3 lesions at least 5 x 5 mm that are accessible for 4 mm punch biopsy PATIENT CHARACTERISTICS: Age 18 and over Performance status Karnofsky 60-100% Life expectancy At least 3 months Hematopoietic Hemoglobin ≥ 8.0 g/dL Absolute neutrophil count ≥ 1,000/mm^3 Platelet count ≥ 75,000/mm^3 Hepatic AST and ALT ≤ 2.5 times upper limit of normal Bilirubin normal Patients with elevated bilirubin secondary to indinavir or atazanavir allowed provided total bilirubin is < 3.5 mg/dL AND direct bilirubin is normal No acute or known chronic liver disease (e.g., chronic active hepatitis or cirrhosis) Hepatitis C infection with minimal or no fibrosis on liver biopsy allowed Renal Creatinine ≤ 1.5 mg/dL OR Creatinine clearance > 60 mL/min Cardiovascular No New York Heart Association class III or IV cardiac disease No congestive heart failure No myocardial infarction within the past 6 months Other Not pregnant or nursing Negative pregnancy test Fertile patients must use effective barrier contraception during and for 3 months after study participation No concurrent active opportunistic infection No other severe and/or life-threatening medical disease No other malignancy within the past 5 years except clinically insignificant malignancy not requiring active intervention, basal cell skin cancer, or carcinoma in situ of the cervix PRIOR CONCURRENT THERAPY: Biologic therapy More than 4 weeks since prior biologic therapy for KS More than 2 weeks since prior granulocyte colony-stimulating factor No concurrent biologic agents for KS Chemotherapy More than 4 weeks since prior chemotherapy for KS (6 weeks for nitrosoureas or mitomycin) No concurrent chemotherapy for KS, including systemic cytotoxic chemotherapy Endocrine therapy No concurrent systemic corticosteroid therapy except replacement doses Radiotherapy See Disease Characteristics More than 4 weeks since prior radiotherapy for KS No concurrent radiotherapy for KS Surgery More than 2 weeks since prior major surgery Other No prior imatinib mesylate More than 60 days since prior local therapy to any KS indicator lesion unless the lesion has progressed since treatment More than 4 weeks since prior investigational therapy for KS More than 4 weeks since other prior therapy for KS More than 14 days since prior acute treatment for an infection or other serious medical illness No concurrent warfarin No concurrent grapefruit juice No other concurrent therapy for KS No other concurrent investigational drugs Concurrent antiretroviral therapy required except for patients who have exhausted all available treatment options

Sites / Locations

  • Moores UCSD Cancer Center
  • USC/Norris Comprehensive Cancer Center and Hospital
  • Jonsson Comprehensive Cancer Center at UCLA
  • Desert Regional Medical Center Comprehensive Cancer Center
  • UCSF Comprehensive Cancer Center
  • University of Miami Sylvester Comprehensive Cancer Center - Miami
  • Robert H. Lurie Comprehensive Cancer Center at Northwestern University
  • Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
  • Beth Israel Deaconess Medical Center
  • Siteman Cancer Center at Barnes-Jewish Hospital
  • Albert Einstein Cancer Center at Albert Einstein College of Medicine
  • Memorial Sloan - Kettering Cancer Center
  • Case Comprehensive Cancer Center
  • Joan Karnell Cancer Center at Pennsylvania Hospital
  • Floyd & Delores Jones Cancer Institute at Virginia Mason Medical Center

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Imatinib mesylate

Arm Description

Imatinib mesylate (Gleevec) taken 400 mg orally once a day for up to 6 months

Outcomes

Primary Outcome Measures

Proportion of Patients Who Achieve a Clinical Response
Clinical response = Complete Response (absence of residual disease) or Partial Response defined as no new lesions (skin or oral), or no new visceral sites of involvement (or the appearance or worsening of tumor-associated edema or effusions); AND 50% or greater decrease in the number of lesions lasting for >4 weeks; OR Complete flattening of at least 50% of all previously raised lesions OR A 50% decrease in the sum of the products of the largest perpendicular diameters of the marker lesions

Secondary Outcome Measures

Inhibition of Platelet-derived Growth Factor-receptor as Assessed by Immunohistochemistry
Cytokine Profiles Before and After Imatinib Therapy
Pharmacokinetic Profile of Imatinib and Antiretrovirals
Mechanisms of Primary and Secondary Resistance to Imatinib Therapy
Mutations in the juxtamembrane or kinase membrane of the c-kit or PDGF receptors at baseline or time of progression
Viral Transcription Profile of Kaposi's Sarcoma-associated Herpesvirus

Full Information

First Posted
September 7, 2004
Last Updated
May 3, 2018
Sponsor
AIDS Malignancy Consortium
Collaborators
National Cancer Institute (NCI), The Emmes Company, LLC
search

1. Study Identification

Unique Protocol Identification Number
NCT00090987
Brief Title
Imatinib Mesylate in Treating Patients With HIV-Related Kaposi's Sarcoma
Official Title
A Phase II Trial Of Imatinib Mesylate (Gleevec) In Patients With HIV Related Kaposi's Sarcoma
Study Type
Interventional

2. Study Status

Record Verification Date
May 2018
Overall Recruitment Status
Completed
Study Start Date
June 2005 (undefined)
Primary Completion Date
December 2009 (Actual)
Study Completion Date
December 2009 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
AIDS Malignancy Consortium
Collaborators
National Cancer Institute (NCI), The Emmes Company, LLC

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
RATIONALE: Imatinib mesylate may stop the growth of tumor cells by blocking the enzymes necessary for their growth. PURPOSE: This phase II trial is studying how well imatinib mesylate works in treating patients with HIV-related Kaposi's sarcoma.
Detailed Description
OBJECTIVES: Primary Determine clinical response in patients with HIV-related Kaposi's sarcoma treated with imatinib mesylate. Secondary Determine the inhibition of platelet-derived growth factor receptors, as determined by immunohistochemistry, in patients treated with this drug. Determine cytokine profiles before and after treatment with this drug in these patients. Determine the pharmacokinetic profile of this drug and antiretrovirals in these patients. Determine mechanisms of primary and secondary resistance to this drug in these patients. OUTLINE: This is an open-label, multicenter study. Patients receive oral imatinib mesylate once daily. Treatment continues for up to 1 year in the absence of disease progression or unacceptable toxicity. Patients are followed at 30 days. PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study within 1 year.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Sarcoma
Keywords
AIDS-related Kaposi sarcoma, recurrent Kaposi sarcoma

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
30 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Imatinib mesylate
Arm Type
Experimental
Arm Description
Imatinib mesylate (Gleevec) taken 400 mg orally once a day for up to 6 months
Intervention Type
Drug
Intervention Name(s)
imatinib mesylate
Other Intervention Name(s)
Gleevec
Intervention Description
400 mg orally once a day for up to 6 months.
Primary Outcome Measure Information:
Title
Proportion of Patients Who Achieve a Clinical Response
Description
Clinical response = Complete Response (absence of residual disease) or Partial Response defined as no new lesions (skin or oral), or no new visceral sites of involvement (or the appearance or worsening of tumor-associated edema or effusions); AND 50% or greater decrease in the number of lesions lasting for >4 weeks; OR Complete flattening of at least 50% of all previously raised lesions OR A 50% decrease in the sum of the products of the largest perpendicular diameters of the marker lesions
Time Frame
20-24 weeks
Secondary Outcome Measure Information:
Title
Inhibition of Platelet-derived Growth Factor-receptor as Assessed by Immunohistochemistry
Time Frame
12 months
Title
Cytokine Profiles Before and After Imatinib Therapy
Time Frame
12 months
Title
Pharmacokinetic Profile of Imatinib and Antiretrovirals
Time Frame
12 months
Title
Mechanisms of Primary and Secondary Resistance to Imatinib Therapy
Description
Mutations in the juxtamembrane or kinase membrane of the c-kit or PDGF receptors at baseline or time of progression
Time Frame
12 months
Title
Viral Transcription Profile of Kaposi's Sarcoma-associated Herpesvirus
Time Frame
12 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
120 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
DISEASE CHARACTERISTICS: Histologically confirmed Kaposi's sarcoma (KS) involving at least 1 of the following areas: Skin Lymph nodes Oral cavity Gastrointestinal tract* Lungs* NOTE: *Must be asymptomatic or minimally symptomatic AND does not require systemic cytotoxic therapy Serological documentation of HIV infection, as evidenced by positive enzyme-linked immunosorbent assay (ELISA), Western Blot test, or other federally approved licensed HIV test At least 5 measurable, non-irradiated, cutaneous indicator lesions Patients must have 3 lesions at least 5 x 5 mm that are accessible for 4 mm punch biopsy PATIENT CHARACTERISTICS: Age 18 and over Performance status Karnofsky 60-100% Life expectancy At least 3 months Hematopoietic Hemoglobin ≥ 8.0 g/dL Absolute neutrophil count ≥ 1,000/mm^3 Platelet count ≥ 75,000/mm^3 Hepatic AST and ALT ≤ 2.5 times upper limit of normal Bilirubin normal Patients with elevated bilirubin secondary to indinavir or atazanavir allowed provided total bilirubin is < 3.5 mg/dL AND direct bilirubin is normal No acute or known chronic liver disease (e.g., chronic active hepatitis or cirrhosis) Hepatitis C infection with minimal or no fibrosis on liver biopsy allowed Renal Creatinine ≤ 1.5 mg/dL OR Creatinine clearance > 60 mL/min Cardiovascular No New York Heart Association class III or IV cardiac disease No congestive heart failure No myocardial infarction within the past 6 months Other Not pregnant or nursing Negative pregnancy test Fertile patients must use effective barrier contraception during and for 3 months after study participation No concurrent active opportunistic infection No other severe and/or life-threatening medical disease No other malignancy within the past 5 years except clinically insignificant malignancy not requiring active intervention, basal cell skin cancer, or carcinoma in situ of the cervix PRIOR CONCURRENT THERAPY: Biologic therapy More than 4 weeks since prior biologic therapy for KS More than 2 weeks since prior granulocyte colony-stimulating factor No concurrent biologic agents for KS Chemotherapy More than 4 weeks since prior chemotherapy for KS (6 weeks for nitrosoureas or mitomycin) No concurrent chemotherapy for KS, including systemic cytotoxic chemotherapy Endocrine therapy No concurrent systemic corticosteroid therapy except replacement doses Radiotherapy See Disease Characteristics More than 4 weeks since prior radiotherapy for KS No concurrent radiotherapy for KS Surgery More than 2 weeks since prior major surgery Other No prior imatinib mesylate More than 60 days since prior local therapy to any KS indicator lesion unless the lesion has progressed since treatment More than 4 weeks since prior investigational therapy for KS More than 4 weeks since other prior therapy for KS More than 14 days since prior acute treatment for an infection or other serious medical illness No concurrent warfarin No concurrent grapefruit juice No other concurrent therapy for KS No other concurrent investigational drugs Concurrent antiretroviral therapy required except for patients who have exhausted all available treatment options
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Ariela Noy, MD
Organizational Affiliation
Memorial Sloan Kettering Cancer Center
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Henry Koon, MD
Organizational Affiliation
Beth Israel Deaconess Medical Center
Official's Role
Study Chair
Facility Information:
Facility Name
Moores UCSD Cancer Center
City
La Jolla
State/Province
California
ZIP/Postal Code
92093-0658
Country
United States
Facility Name
USC/Norris Comprehensive Cancer Center and Hospital
City
Los Angeles
State/Province
California
ZIP/Postal Code
90089-9181
Country
United States
Facility Name
Jonsson Comprehensive Cancer Center at UCLA
City
Los Angeles
State/Province
California
ZIP/Postal Code
90095-1781
Country
United States
Facility Name
Desert Regional Medical Center Comprehensive Cancer Center
City
Palm Springs
State/Province
California
ZIP/Postal Code
92262
Country
United States
Facility Name
UCSF Comprehensive Cancer Center
City
San Francisco
State/Province
California
ZIP/Postal Code
94115
Country
United States
Facility Name
University of Miami Sylvester Comprehensive Cancer Center - Miami
City
Miami
State/Province
Florida
ZIP/Postal Code
33136
Country
United States
Facility Name
Robert H. Lurie Comprehensive Cancer Center at Northwestern University
City
Chicago
State/Province
Illinois
ZIP/Postal Code
60611-3013
Country
United States
Facility Name
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
City
Baltimore
State/Province
Maryland
ZIP/Postal Code
21231-2410
Country
United States
Facility Name
Beth Israel Deaconess Medical Center
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02215
Country
United States
Facility Name
Siteman Cancer Center at Barnes-Jewish Hospital
City
Saint Louis
State/Province
Missouri
ZIP/Postal Code
63110
Country
United States
Facility Name
Albert Einstein Cancer Center at Albert Einstein College of Medicine
City
Bronx
State/Province
New York
ZIP/Postal Code
10461
Country
United States
Facility Name
Memorial Sloan - Kettering Cancer Center
City
New York
State/Province
New York
ZIP/Postal Code
10021
Country
United States
Facility Name
Case Comprehensive Cancer Center
City
Cleveland
State/Province
Ohio
ZIP/Postal Code
44106-5065
Country
United States
Facility Name
Joan Karnell Cancer Center at Pennsylvania Hospital
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19106
Country
United States
Facility Name
Floyd & Delores Jones Cancer Institute at Virginia Mason Medical Center
City
Seattle
State/Province
Washington
ZIP/Postal Code
98101
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
16687713
Citation
Berman E, Nicolaides M, Maki RG, Fleisher M, Chanel S, Scheu K, Wilson BA, Heller G, Sauter NP. Altered bone and mineral metabolism in patients receiving imatinib mesylate. N Engl J Med. 2006 May 11;354(19):2006-13. doi: 10.1056/NEJMoa051140.
Results Reference
background
PubMed Identifier
16862153
Citation
Kerkela R, Grazette L, Yacobi R, Iliescu C, Patten R, Beahm C, Walters B, Shevtsov S, Pesant S, Clubb FJ, Rosenzweig A, Salomon RN, Van Etten RA, Alroy J, Durand JB, Force T. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med. 2006 Aug;12(8):908-16. doi: 10.1038/nm1446. Epub 2006 Jul 23.
Results Reference
background
PubMed Identifier
24378417
Citation
Koon HB, Krown SE, Lee JY, Honda K, Rapisuwon S, Wang Z, Aboulafia D, Reid EG, Rudek MA, Dezube BJ, Noy A. Phase II trial of imatinib in AIDS-associated Kaposi's sarcoma: AIDS Malignancy Consortium Protocol 042. J Clin Oncol. 2014 Feb 10;32(5):402-8. doi: 10.1200/JCO.2012.48.6365. Epub 2013 Dec 30.
Results Reference
background

Learn more about this trial

Imatinib Mesylate in Treating Patients With HIV-Related Kaposi's Sarcoma

We'll reach out to this number within 24 hrs